30.71

1.54% -0.48

After Hours: 30.71

Collegium Pharmaceutical Inc (COLL)

Overview News Price History Option Chain Financials Discussions Forecast

Collegium Pharmaceutical Inc stock is traded at $30.71, with a volume of 585.03K. It is down -1.54% in the last 24 hours and down -11.50% over the past month. Collegium Pharmaceutical Inc is a specialty pharmaceutical company. The company is engaged in developing and planning to commercialize abuse-deterrent products that incorporate its patented DETERx platform technology for the treatment of chronic pain and other diseases. The DETERx platform technology is designed to maintain the extended-release and safety profiles of highly abused drugs in the face of various methods including chewing, crushing, and dissolving. Its product portfolio includes Xtampza ER, which is an abuse-deterrent, extended-release, oral formulation of oxycodone; and Nucynta Products, which are extended-release and immediate-release formulations of tapentadol; Belbuca, and Symproic.

Previous Close:

$31.19

Open:

$31.23

24h Volume:

585.03K

Relative Volume:

1.48

Market Cap:

$1.02B

Revenue:

$566.77M

Net Income/Loss:

$48.16M

P/E Ratio:

-83.00

EPS:

-0.37

Net Cash Flow:

$274.29M

1W Performance:

+2.37%

1M Performance:

-11.50%

6M Performance:

-10.34%

1Y Performance:

+18.75%

1-Day Range:

$30.67

$31.70

1-Week Range:

$29.80

$31.70

52-Week Range:

$25.16

$42.29

Collegium Pharmaceutical Inc Stock (COLL) Company Profile

Name

Collegium Pharmaceutical Inc

Sector

Healthcare (1200)

Industry

Drug Manufacturers - Specialty & Generic (87)

Phone

781-713-3699

Address

100 TECHNOLOGY CENTER DRIVE, STOUGHTON, MA

Employee

197

Twitter

Next Earnings Date

2024-11-07

Latest SEC Filings

COLL's Discussions on Twitter

Compare COLL with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
COLL Collegium Pharmaceutical Inc	30.71	1.02B	566.77M	48.16M	274.29M	-0.37
ZTS Zoetis Inc	176.74	80.59B	9.15B	2.43B	2.31B	4.92
HLN Haleon Plc Adr	9.72	44.17B	14.26B	1.55B	0	0.3327
TAK Takeda Pharmaceutical Co Adr	13.57	42.61B	30.27B	1.93B	3.45B	0.444
TEVA Teva Pharmaceutical Industries Ltd Adr	16.57	18.77B	16.77B	-959.00M	1.37B	-2.00
VTRS Viatris Inc	13.22	15.73B	15.05B	-883.30M	1.89B	1.53

Collegium Pharmaceutical Inc Stock (COLL) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Jul-30-24	Upgrade	H.C. Wainwright	Neutral → Buy
Jun-07-24	Upgrade	Jefferies	Hold → Buy
May-10-24	Downgrade	Needham	Buy → Hold
May-10-24	Downgrade	Piper Sandler	Overweight → Neutral
Jan-04-24	Downgrade	Jefferies	Buy → Hold
Aug-25-23	Reiterated	Needham	Buy
May-02-23	Resumed	Jefferies	Buy
Aug-08-22	Downgrade	H.C. Wainwright	Buy → Neutral
Feb-15-22	Upgrade	Cantor Fitzgerald	Neutral → Overweight
Aug-06-21	Downgrade	Cantor Fitzgerald	Overweight → Neutral
Jan-11-21	Reiterated	H.C. Wainwright	Buy
Jul-14-20	Initiated	BWS Financial	Sell
May-27-20	Initiated	Guggenheim	Neutral
Feb-19-20	Resumed	Jefferies	Buy
Oct-30-19	Reiterated	Needham	Buy
May-03-19	Resumed	H.C. Wainwright	Buy
Apr-12-19	Resumed	Janney	Buy
Mar-20-19	Initiated	SunTrust	Hold
Jan-16-19	Reiterated	Needham	Buy
Mar-08-18	Reiterated	H.C. Wainwright	Buy
Feb-07-18	Reiterated	Needham	Buy
Dec-05-17	Reiterated	Needham	Buy
Sep-11-17	Initiated	H.C. Wainwright	Buy
May-11-17	Reiterated	Needham	Buy
Sep-13-16	Initiated	Gabelli & Co	Buy
Jun-01-15	Initiated	Jefferies	Buy
Jun-01-15	Initiated	Needham	Buy
Jun-01-15	Initiated	Piper Jaffray	Overweight

View All

Collegium Pharmaceutical Inc Stock (COLL) Latest News

Nov 27, 2024

Rubric Capital Management LP Lowers Stock Position in Collegium Pharmaceutical, Inc. (NASDAQ:COLL) - MarketBeat

Nov 27, 2024

Brokerages Set Collegium Pharmaceutical, Inc. (NASDAQ:COLL) Target Price at $42.60 - Defense World

Nov 27, 2024

Nov 26, 2024

Collegium Pharmaceutical: Strong Growth With Pain Management And ADHD Expansion - Seeking Alpha

Nov 26, 2024

Massachusetts Financial Services Co. MA Increases Stock Holdings in Collegium Pharmaceutical, Inc. (NASDAQ:COLL) - MarketBeat

Nov 26, 2024

Nov 24, 2024

Collegium Pharmaceutical, Inc. (NASDAQ:COLL) Receives Average Recommendation of "Moderate Buy" from Brokerages - MarketBeat

Nov 24, 2024

Nov 22, 2024

Pacer Advisors Inc. Sells 818,721 Shares of Collegium Pharmaceutical, Inc. (NASDAQ:COLL) - MarketBeat

Nov 22, 2024

Nov 20, 2024

Is the Options Market Predicting a Spike in Collegium Pharmaceutical (COLL) Stock? - MSN

Nov 20, 2024

Nov 18, 2024

Amalgamated Bank Has $372,000 Holdings in Collegium Pharmaceutical, Inc. (NASDAQ:COLL) - Defense World

Nov 18, 2024

121,446 Shares in Collegium Pharmaceutical, Inc. (NASDAQ:COLL) Acquired by Empowered Funds LLC - MarketBeat

Nov 18, 2024

Victory Capital Management Inc. Purchases 215,874 Shares of Collegium Pharmaceutical, Inc. (NASDAQ:COLL) - MarketBeat

Nov 18, 2024

Nov 14, 2024

Shareholders Can Be Confident That Collegium Pharmaceutical's (NASDAQ:COLL) Earnings Are High Quality - Simply Wall St

Nov 14, 2024

Collegium Pharmaceutical's (NASDAQ:COLL) Performance Is Even Better Than Its Earnings Suggest - Yahoo Finance

Nov 14, 2024

Rubric Capital Management LP Adjusts Stake in Collegium Pharmace - GuruFocus.com

Nov 14, 2024

Nov 13, 2024

Is Collegium Pharmaceutical (COLL) a Great Value Stock Right Now? - MSN

Nov 13, 2024

Nov 12, 2024